Tango Therapeutics, Inc. (TNGX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Tango Therapeutics reported revenue of $62.4M, up 48.3% from $42.1M the year before. Net income was -$101.6M (a -162.9% net margin), or -$0.87 per diluted share. Operating margin was -178.4%. Operating activities generated -$138.9M of cash, leaving -$139.9M of free cash flow. At fiscal year end, Tango Therapeutics held $398.7M in total assets against $52.5M in total liabilities, including $112.3M of cash and equivalents.
Open the full interactive Tango Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Tango Therapeutics Key Stats
| Share Price | $22.22 |
|---|---|
| Market Cap | $3.33B |
| Revenue YoY Growth | +48.3% |
| 52-Week Range | $7.49 – $32.90 |
| Shares Outstanding | 149.9 million (basic, 2026 Q2) |
Tango Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $37.0M | $24.9M | $36.5M | $42.1M | $62.4M |
| Operating Income | -$58.2M | -$111.1M | -$114.2M | -$145.6M | -$111.3M |
| Pre-Tax Income | -$57.9M | -$108.1M | -$101.6M | -$130.1M | -$101.6M |
| Income Tax | $292,000 | $54,000 | $134,000 | $208,000 | $4,000 |
| Net Income | -$58.2M | -$108.2M | -$101.7M | -$130.3M | -$101.6M |
| Diluted EPS | -$0.94 | -$1.23 | -$1.08 | -$1.19 | -$0.87 |
Tango Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $53.8M | $0 | $0 | $0 |
| Net Income | $15.9M | -$38.7M | -$45.5M | -$55.3M |
| Diluted EPS | $0.13 | -$0.33 | -$0.32 | -$0.37 |
Tango Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $142.7M | $60.0M | $66.4M | $69.5M | $112.3M |
| Current Assets | $492.3M | $375.3M | $346.5M | $266.3M | $353.8M |
| Total Assets | $500.2M | $436.5M | $402.6M | $316.5M | $398.7M |
| Current Liabilities | $40.7M | $55.5M | $45.9M | $38.2M | $21.7M |
| Total Liabilities | $155.4M | $187.0M | $149.5M | $117.0M | $52.5M |
| Shareholders' Equity | $344.7M | $249.5M | $253.1M | $199.5M | $346.2M |
Tango Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$59.5M | -$109.1M | -$118.0M | -$131.5M | -$138.9M |
| Cash From Investing | -$183.4M | $26.4M | $41.4M | $86.1M | -$40.9M |
| Cash From Financing | $357.3M | $1.6M | $82.4M | $47.7M | $222.5M |
| Free Cash Flow | -$61.4M | -$116.8M | -$119.5M | -$132.3M | -$139.9M |
Figures from Tango Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Tango Therapeutics financials page for every line item.
Tango Therapeutics Company Profile
| Ticker | TNGX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001819133 |
Frequently Asked Questions
What was Tango Therapeutics' revenue in fiscal 2025?
Tango Therapeutics (TNGX) reported revenue of $62.4M for fiscal 2025.
What is Tango Therapeutics' annual revenue history?
Tango Therapeutics' annual revenue by fiscal year: 2021: $37.0M; 2022: $24.9M; 2023: $36.5M; 2024: $42.1M; 2025: $62.4M.
What was Tango Therapeutics' net income in fiscal 2025?
Tango Therapeutics reported net income of -$101.6M for fiscal 2025.
What was Tango Therapeutics' earnings per share (EPS) in fiscal 2025?
Tango Therapeutics' diluted EPS was -$0.87 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Tango Therapeutics generate in fiscal 2025?
Tango Therapeutics generated -$139.9M of free cash flow in fiscal 2025.
What was Tango Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Tango Therapeutics reported revenue of $0.
How many shares of Tango Therapeutics are outstanding?
Tango Therapeutics reported a weighted average of 149.9 million basic shares outstanding in 2026 Q2.
What is Tango Therapeutics' market cap?
Based on its latest closing price, Tango Therapeutics (TNGX) has a market capitalization of about $3.33B.
When does Tango Therapeutics' fiscal year end?
Tango Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Tango Therapeutics headquartered?
Tango Therapeutics lists its business address in Boston, Massachusetts in its SEC filings.